Ranger demonstrated consistently high primary patency versus uncoated PTA (RANGER II) and IN.PACT (COMPARE) at 12 months¹⁻²
Ranger demonstrated similar primary patency to IN.PACT™ DCB, using around half the paclitaxel dose at 12 months²
Ranger demonstrated a significantly lower 12-month CD-TLR rate versus uncoated PTA, resulting in a 67% relative reduction in repeat procedures¹
1. Sachar R et al. RANGER II SFA Investigators. 1-year results from the RANGER II SFA randomized trial of the Ranger drug-coated balloon. JACC Cardiovasc Interv. 2021;10:1123–1133.
2. Steiner S, et al. COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions. Eur Heart J. 2020;41:2541–2552.
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.